Lunit Inc. (328130) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Lunit Inc. stock KRW 12,384, price KRW 15,820, that is 21.7% below the price, quality 26 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Lunit Inc.
328130 · KQExpensive (fair value 22% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
52‑month range 4,252 KRW – 56,074 KRW · fair‑value band 9,288 KRW – 15,480 KRW · the 15,820 KRW price screens above the 12,384 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Every Wednesday you see whether Lunit is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer.
Show moreShow less
The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research.
Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
Stock analysis
Lunit Inc. (328130) currently trades at 15,820 KRW, while our estimate is 12,384 KRW, 22% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 9,288 KRW (bear) to 15,480 KRW (bull), the price of 15,820 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Lunit Inc. reported revenue of 83.1B KRW in FY2025 versus 6.6B KRW in FY2021, a compound +88.1%/yr. Reported net income was −47.4B KRW in FY2025.
Key figures
Market cap 1.1T KRW (≈ $841M) Small · P/S ratio 12.1 · EPS (TTM) −747.92 KRW · Net margin −60.7% · Return on equity −23.5% · Return on assets (EBIT) −30.9% (5-year average) · Operating margin −70.4% · Revenue (TTM) 91.8B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 93% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −22%, 328130 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
328130 screens overvalued: fair value 22% below the price. Compare with Veeva Systems Inc →
Compare Lunit Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 140 stocks
Valuation Multiplesvs Health Information Services median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- PEG screener for stocks with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Doximity, Inc DOCS | $32.77 | $36.67 | +12% | vs 328130 |
| Veeva Systems Inc VEEV | $299.28 | $329.21 | +10% | vs 328130 |
| HealthEquity, Inc HQY | $104.58 | $115.04 | +10% | vs 328130 |
| Waystar Holding WAY | $28.11 | $29.10 | +4% | vs 328130 |
| Tempus AI, Inc TEM | $64.76 | $52.58 | −19% | vs 328130 |
| HeartFlow, Inc HTFL | $46.86 | $30.50 | −35% | vs 328130 |
| Hinge Health, Inc HNGE | $121.29 | $51.25 | −58% | vs 328130 |
| Pro Medicus Limited PME | A$201.65 | A$82.80 | −59% | vs 328130 |
| BrightSpring Health Services, Inc BTSG | $71.37 | $25.72 | −64% | vs 328130 |
| XtalPi Holdings 2228 | HK$5.32 | HK$1.53 | −71% | vs 328130 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Lunit Inc. (328130) overvalued or undervalued?
What is the fair value of 328130?
What is the quality score of 328130?
What is the price target for Lunit Inc. (328130)?
What is the Lunit Inc. stock forecast for 2026?
What is the revenue of Lunit Inc. (328130)?
What is the intrinsic value of Lunit Inc. (328130)?
Is Lunit Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 328130?
How much is Lunit Inc. worth?
What do the bullish and bearish scenarios say about 328130?
How solid is the balance sheet of Lunit Inc. (328130)?
How far is 328130 from its 52-week high?
Which stocks are comparable to Lunit Inc.?
Is Lunit Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Lunit Inc. (328130)?
What should I pay attention to with Lunit Inc. right now?
Key figures of Lunit Inc.
How large is the market capitalisation of Lunit Inc. (328130)?
What is the P/S ratio of Lunit Inc. (328130)?
What are the earnings per share of Lunit Inc. (328130)?
What is the net margin of Lunit Inc. (328130)?
What is the return on equity of Lunit Inc. (328130)?
What is the EBIT return on assets of Lunit Inc. (328130)?
What is the operating margin of Lunit Inc. (328130)?
How fast is revenue growing at Lunit Inc. (328130)?
How much free cash flow does Lunit Inc. (328130) generate?
How much net debt does Lunit Inc. (328130) carry?
Watch Lunit Inc. in the live analysis
One click puts Lunit Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.